Extrait

PART A-To evaluate the effect of repeat doses of GSK2118436 on the single dose PK of S-warfarin in subjects with BRAF mutant solid tumors. PART B & C-To evaluate the effect of repeat oral doses of an inhibitor, ketoconazole (Part B) or gemfibrozil (Part C) on the repeat dose PK of GSK2118436 in subjects with BRAF mutant solid tumors • To evaluate the single- and repeat-dose PK of GSK2118436 and its metabolites (GSK2285403, GSK2167542, GSK2298683) following administration of GSK2118436 75 mg HPMC capsules(or lower dose, based on emerging PK data) PART D (REPEAT DOSING WITH GSK2118436) To evaluate the single- and repeat dose PK of GSK2118436 and its metabolites (GSK2285403, GSK2167542, GSK2298683) following administration of GSK2118436 150 mg BID HPMC capsules. PART B & D (REPEAT DOSING WITH GSK2118436) SEE PROTOCOL P25

Critère d'inclusion

• Skin cancer

Liens

• ictrp
• euctr